Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Sep;163(3):1013-20.
doi: 10.1016/s0002-9440(10)63461-x.

Relevance of nuclear and cytoplasmic von hippel lindau protein expression for renal carcinoma progression

Peter Schraml  1 , Alexander Hergovich, Florian Hatz, Mahul B Amin, So D Lim, Wilhelm Krek, Michael J Mihatsch, Holger Moch
Affiliations

Relevance of nuclear and cytoplasmic von hippel lindau protein expression for renal carcinoma progression

Peter Schraml et al. Am J Pathol. 2003 Sep.

Erratum in

  • Am J Pathol. 2003 Dec;163(6):2645. Hergovitz Alexander [corrected to Hergovich Alexander]

Abstract

Alterations of the von Hippel-Lindau tumor-suppressor gene (VHL) on 3p25-p26 are frequent in clear-cell renal-cell carcinoma (RCC). The VHL protein (pVHL) is implicated in cell-cycle control and gene regulation, and requires transcription-dependent nuclear-cytoplasmic trafficking for its function. There are two biologically active VHL protein isoforms: pVHL(30) and pVHL(19). To study prevalence, subcellular expression and biological significance of pVHL in renal tumors, tissue microarrays with renal-cell carcinomas were immunohistochemically examined for pVHL expression. Antibodies against both protein isoforms (anti-pVHL(30)/pVHL(19)) and against pVHL(30) (anti-pVHL(30); Ig33) were used. The anti-pVHL(30)/pVHL(19) antibody showed nuclear and cytoplasmic pVHL expression, whereas the anti-pVHL(30) antibody (Ig33) detected cytoplasmic pVHL expression, suggesting that the distribution of VHL protein isoforms varies in the nuclear and cytoplasmic compartments of renal tumors. There were 175 of 398 primary clear-cell RCCs (44%) with both nuclear and cytoplasmic pVHL expression. Seventy-seven clear-cell RCCs (19%) showed only nuclear, 22 (6%) showed only cytoplasmic, and 124 tumors (31%) showed no pVHL expression. Notably, combined nuclear and cytoplasmic pVHL expression was associated with low histological grade (P < 0.0001), early tumor stage (P < 0.01), and better prognosis (P < 0.01). These results imply that alteration of subcellular pVHL trafficking is of potential relevance for the biological behavior of clear-cell RCC.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
A: Renal-tumor TMA after immunostaining with anti-pVHL30/pVHL19-antibody. B to E: Examples of pVHL expression on a renal-tumor TMA. B: Nuclear and cytoplasmic pVHL in normal renal tubules. C: Nuclear and cytoplasmic pVHL in chromophobe RCC. D: Nuclear pVHL in clear-cell RCC. E: Cytoplasmic pVHL in papillary RCC.
Figure 2.
Figure 2.
Nuclear and cytoplasmic pVHL expression and tumor-specific survival in clear-cell RCC. A: All clear-cell RCC with and without nuclear staining. B: All clear-cell RCC with and without cytoplasmic staining. C: All clear-cell RCC with and without combined nuclear and cytoplasmic pVHL expression and its association with tumor-specific survival in clear-cell RCC.
Figure 3.
Figure 3.
LOH at microsatellite loci D3S1597 and D3S1307 on chromosome 3p25-p26 in two clear-cell RCCs.
See this image and copyright information in PMC

References

    1. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, Schmidt L, Zhou F, Li H, Wei MH, Chen F, Glenn G, Choyke P, Walther MM, Weng Y, Duan D-SR, Dean M, Glavac D, Richards F, Crossey P, Ferguson-Smith MA, LePaslier D, Chumakov I, Cohen D, Chinault AC, Maher ER, Lineham WM, Zbar B, Lerman MI: Identification of the von Hippel-Lindau disease tumor-suppressor gene Science 1993, 260:1317-1320 - PubMed
    1. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM, Lubensky J, Duan DR, Florence C, Potatti R, Walther MM, Bander NH, Grossman HB, Brach H, Pomer S, Brooks JD, Issacs WB, Lerman MI, Zber B, Lineham WM: Mutations of the VHL tumour suppressor gene in renal carcinoma Nat Genet 1994, 7:85-90 - PubMed
    1. Brauch H, Weirich G, Brieger J, Glavac D, Rodl H, Eichinger M, Feurer M, Weidt E, Puranakanitstha C, Neuhaus C, Pomer S, Brenner W, Schirmacher P, Storkel S, Rotter M, Masera A, Gugeler N, Decker HJ: VHL alterations in human clear-cell renal-cell carcinoma: association with advanced tumor stage and a novel hot spot mutation Cancer Res 2000, 60:1942-1948 - PubMed
    1. Schraml P, Struckmann K, Hatz F, Sonnet S, Kully C, Gasser T, Sauter G, Mihatsch MJ, Moch H: VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear-cell renal-cell carcinoma J Pathol 2002, 196:186-193 - PubMed
    1. Chen F, Kishida T, Duh FM, Renbaum P, Orcutt ML, Schmidt L, Zbar B: Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor-suppressor gene Cancer Res 1995, 55:4804-4807 - PubMed

Publication types